The economic costs of heart attack and chest pain (Acute Coronary Syndrome)

Derek Chew, David B. Brieger, Ren Tan, Jenny Coutts, Margaret Flaherty, Ineke Bleeker, Alex Brown, Graham Neville, Tony Arvidsson, Rohan Greenland, Andrew Boyden, Kim Goodman, Debbie White, Paul Middleton, Linda Soars, Deon Gouws, Paul Dale, Stuart Englund, Fiona Bailey

    Research output: Book/ReportCommissioned reportpeer-review


    Access Economics was commissioned by Eli Lilly to estimate the economic costs of Heart Attack and Chest Pain (Acute Coronary Syndrome-ACS) in Australia for 2009. In addition, an objective was to investigate current gaps in ACS treatment and clinical need, and highlight areas of treatment where further investment may result in significant benefits through a reduction in the burden of disease and improvements in efficiency and quality of care.

    To estimate the economic costs of ACS, this study has used the comprehensive cost of illness framework used throughout the world. In brief, the study consists of the following sections:
    ■ epidemiology of ACS in Australia;
    ■ direct health care system costs associated with treatment;
    ■ indirect financial and economic costs;
    ■ value of the loss in health associated with morbidity and mortality; and
    ■ the future of ACS management in Australia.
    Original languageEnglish
    Place of PublicationAustralia
    PublisherAccess Economics
    Number of pages86
    Publication statusPublished - Jun 2009


    Dive into the research topics of 'The economic costs of heart attack and chest pain (Acute Coronary Syndrome)'. Together they form a unique fingerprint.

    Cite this